| NCT ID | NCT02993796 |
| Status | Recruiting |
| Phase | — |
| Sponsor | State University of New York at Buffalo |
| Condition | Krabbe Disease |
| Study Type | OBSERVATIONAL |
| Enrollment | 60 participants |
| Start Date | 2014-09 |
| Primary Completion | 2026-09 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 60 participants in total. It began in 2014-09 with a primary completion date of 2026-09.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to develop a clinical database of individuals diagnosed with Krabbe disease in order to determine which symptoms herald the onset of clinical disease in the various phenotypes of Krabbe disease; to determine whether level of GALC enzyme activity, or a specific genetic mutation predict the clinical course; and to determine which neurodiagnostic tests predict onset and/or severity of the disease.
Eligibility Criteria
Inclusion Criteria: * Anyone diagnosed with Krabbe disease * Anyone at-risk for Krabbe disease * Family members of someone diagnosed with, or at-risk for, Krabbe disease. Exclusion Criteria: * Anyone who is not diagnosed with, or at-risk for, Krabbe disease * Anyone who is not a family member of someone diagnosed with, or at-risk for, Krabbe disease
Contact & Investigator
Thomas J. Langan, MD
PRINCIPAL INVESTIGATOR
Clinical Director, Clinical Research, Institute for Myelin and Glial Exploration
Frequently Asked Questions
Who can join the NCT02993796 clinical trial?
This trial is open to participants of all sexes, studying Krabbe Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT02993796 currently recruiting?
Yes, NCT02993796 is actively recruiting participants. Contact the research team at tjlangan@buffalo.edu for enrollment information.
Where is the NCT02993796 trial being conducted?
This trial is being conducted at Buffalo, United States.
Who is sponsoring the NCT02993796 clinical trial?
NCT02993796 is sponsored by State University of New York at Buffalo. The principal investigator is Thomas J. Langan, MD at Clinical Director, Clinical Research, Institute for Myelin and Glial Exploration. The trial plans to enroll 60 participants.